SCHEMBL3700787

SCHEMBL3700787

COc1ccc(C(OCCC(O)CCNC(=O)OCc2ccccc2)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ATM Q13315 1/20 0.44
SLC1A3 P43003 1/20 0.43
SLC1A1 P43005 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
GAA P10253 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
ACHE P22303 1/20 0.43
CTSL P07711 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
HTT P42858 1/20 0.42
SLC6A1 P30531 2/20 0.42
SLC6A11 P48066 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3691998 0.92 TGM2 (0.45) L3MBTL1MAPTLMNASMN1; SMN2CA1
SCHEMBL3689628 0.92 TGM2 (0.45) L3MBTL1MAPTLMNASMN1; SMN2CA1
SCHEMBL7642842 0.88 CPB1 (0.47) MAPTCA1CA2
SCHEMBL524569 0.86 SLC6A11 (0.47) SMN1; SMN2NPC1RAB9ASLC6A1SLC6A11
SCHEMBL29450730 0.85 LMNA (0.62) L3MBTL1MAPTLMNASMN1; SMN2ATM
SCHEMBL14168068 0.82 LMNA (0.49) L3MBTL1MAPTLMNASMN1; SMN2SLC1A3
SCHEMBL6419856 0.81 MEN1 (0.44) L3MBTL1MAPTLMNASMN1; SMN2ATM
SCHEMBL3693004 0.80 CA1 (0.46) L3MBTL1MAPTLMNASMN1; SMN2ATM
SCHEMBL7640180 0.78 MEN1 (0.42) L3MBTL1MAPTLMNASMN1; SMN2ATM
SCHEMBL7639356 0.78 MEN1 (0.44) L3MBTL1MAPTLMNASMN1; SMN2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081949-B1 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE GE HEALTHCARE DHARMACON INC (US) 2014-12-10 EP disclosed
US-8809514-B2 Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference GE HEALTHCARE DHARMACON, INC. (US) 2014-08-19 US disclosed
US-8501706-B2 Duplex oligonucleotide complexes and methods for gene silencing by RNA interference DHARMACON, INC. (US) 2013-08-06 US disclosed
EP-2064223-B1 Duplex oligonucleotide complexes and methods for gene silencing by RNA interference DHARMACON INC (US) 2013-04-24 EP disclosed
US-20120322855-A1 Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference DHARMACON, INC. (US) 2012-12-20 US disclosed
US-8252755-B2 Duplex oligonucleotide complexes and methods for gene silencing by RNA interference DHARMACON, INC. (US) 2012-08-28 US disclosed
US-20100093085-A1 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC (US) 2010-04-15 US disclosed
EP-2081949-A2 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE Dharmacon, Inc. (US) 2009-07-29 EP disclosed
EP-2064223-A2 DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE Dharmacon, Inc. (US) 2009-06-03 EP disclosed
US-20080085869-A1 Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism DHARMACON, INC. (US) 2008-04-10 US disclosed
WO-2008036825-A2 DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC. (US) 2008-03-27 WO disclosed
WO-2008036841-A2 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC. (US) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093085-A1 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE SNRPE, DCLRE1B, RNASE1 L3MBTL1 4/4885MAPT 4328/4885LMNA 1804/4885
US-20120322855-A1 Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference SNRPE, AGO2, DCLRE1B L3MBTL1 43/4885MAPT 4643/4885LMNA 2348/4885
US-20080085869-A1 Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism SRRT, SNRPE, SSBP1 L3MBTL1 115/4885MAPT 3499/4885LMNA 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.